660 completed, 190 unknown, 156 terminated, 151 recruiting. 806 Phase 2, 399 Phase 1, 209 Phase 3, 17 Not applicable, 12 Early Phase 1.
Follow Irinotecan: new trials by email Literature Review of Irinotecan trials Research Report on Irinotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies PM54, Irinotecan, Doxorubicin - Advanced Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | PharmaMar | 231 | 2026-11-12 | 2026-09-24 |
| Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma Pembrolizumab and Irinotecan - Unresectable or Metastatic Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 46 | 2026-11-01 | 2026-09-14 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. FH-006, Paclitaxel, Docetaxel, Irinotecan - Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 480 | 2026-10-13 | 2026-10-27 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer | Phase 1 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 120 | 2026-09-30 | 2026-10-16 |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma ATG-022, Docetaxel or Irinotecan - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Antengene Biologics Limited | 380 | 2026-09-17 | 2026-10-29 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma Valproic Acid (VPA), Irinotecan, Simvastatin - Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Inova Health Care Services | 52 | 2026-09-04 | 2026-09-21 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer | Not applicable | Not yet recruiting | IMGT Co., Ltd. | 360 | 2026-09-01 | 2026-07-15 |
| A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel - Gastric Cancer Peritoneal Metastasis (GCPM) | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 40 | 2026-09-01 | 2026-08-25 |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-08-31 | 2026-06-23 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
Showing 20 of 1312. Sign in to see all of them.
Colorectal Neoplasms (416) · Colonic Neoplasms (152) · Rectal Neoplasms (152) · Pancreatic Neoplasms (114) · Stomach Neoplasms (111) · Neoplasm Metastasis (90) · Neoplasms (76) · Esophageal Neoplasms (61) · Small Cell Lung Carcinoma (47) · Lung Neoplasms (44) · Neuroblastoma (42) · Carcinoma, Non-Small-Cell Lung (39) · Glioblastoma (39) · Brain Neoplasms (33) · Esophageal Squamous Cell Carcinoma (33)
National Cancer Institute (NCI) (60) · Alliance for Clinical Trials in Oncology (34) · Memorial Sloan Kettering Cancer Center (34) · Fudan University (29) · Sun Yat-sen University (27) · M.D. Anderson Cancer Center (20) · Children's Oncology Group (19) · Pfizer (19) · Eli Lilly and Company (15) · Merck Sharp & Dohme LLC (15) · Gruppo Oncologico del Nord-Ovest (14) · Hoffmann-La Roche (14) · National Cancer Center, Korea (14) · Roswell Park Cancer Institute (14) · SWOG Cancer Research Network (14)
United States (674) · China (237) · France (143) · Italy (106) · South Korea (101) · Canada (100) · Spain (97) · Germany (90) · United Kingdom (76) · Japan (68) · Australia (65) · Belgium (59) · Taiwan (44) · Netherlands (37) · Puerto Rico (35)
David H. Ilson, MD, PhD (9) · Alfredo Falcone, MD (5) · John Souglakos, MD (5) · Zhen Zhang, MD (5) · Annick Desjardins, MD, FRCPC (4) · Emily Slotkin, MD (4)
PMID 32816630, PMID 41252656, PMID 19139178, PMID 21561347, PMID 21742485, PMID 24327518, PMID 26861604, PMID 27275632, PMID 27424289, PMID 27722750, PMID 27986363, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30293873, PMID 31101621, PMID 31268130, PMID 31533931, PMID 31831767, PMID 31882719, PMID 35594613, PMID 37678921, PMID 38603649, PMID 40963055, PMID 10334539, PMID 10615932, PMID 10628373, PMID 12187070, PMID 12196368, PMID 12196376, PMID 12393999, PMID 12467231, PMID 12663720, PMID 12794246, PMID 12794247, PMID 12885811, PMID 12963697, PMID 14630685, PMID 14665611, PMID 14769136, PMID 14769140, PMID 14998842, PMID 15083176, PMID 15470715, PMID 15565574, PMID 15641483, PMID 15668285, PMID 15677624, PMID 15709193
2023 (18), U10CA180886 (14), U10CA031946 (11), U10CA032102 (9), 2016 (8), 2017 (8), U10CA098543 (8), 2009 (7), 2025 (7), P30CA033572 (7), U10CA180888 (7), 2015 (6), P30CA015083 (6), U10CA021115 (6), 2014 (5)